BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//The Life Raft Group - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://liferaftgroup.org
X-WR-CALDESC:Events for The Life Raft Group
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20180311T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20181104T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20190310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20191103T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20200308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20201101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20210314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20211107T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20220313T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20221106T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20230312T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20231105T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:Australia/Melbourne
BEGIN:STANDARD
TZOFFSETFROM:+1100
TZOFFSETTO:+1000
TZNAME:AEST
DTSTART:20200404T160000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+1000
TZOFFSETTO:+1100
TZNAME:AEDT
DTSTART:20201003T160000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+1100
TZOFFSETTO:+1000
TZNAME:AEST
DTSTART:20210403T160000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+1000
TZOFFSETTO:+1100
TZNAME:AEDT
DTSTART:20211002T160000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+1100
TZOFFSETTO:+1000
TZNAME:AEST
DTSTART:20220402T160000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+1000
TZOFFSETTO:+1100
TZNAME:AEDT
DTSTART:20221001T160000
END:DAYLIGHT
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20220615T190000
DTEND;TZID=America/New_York:20220615T200000
DTSTAMP:20260504T201330
CREATED:20220502T151913Z
LAST-MODIFIED:20220502T151913Z
UID:10000232-1655319600-1655323200@liferaftgroup.org
SUMMARY:Updates from ASCO 2022
DESCRIPTION:Webinar\, June 15\, 7-8 pm ET \nASCO (American Society of Clinical Oncology) is an important conference in the oncology community where new scientific research updates are shared. The Life Raft Group is excited to present Dr. Andrew Wagner and Dr. Herbert Loong\, who will summarize abstracts and presentations that were presented during this conference that are relevant to the GIST patient community. \nREGISTERAbout our Presenter:\nAndrew J. Wagner\, MD\nDana-Farber Cancer Institute \nDr. Andrew J. Wagner is the Deputy Chief Medical Officer at Dana-Farber Cancer Institute and the Medical Director of Adult Ambulatory Oncology. As a medical oncologist and translational researcher in the Center for Sarcoma and Bone Oncology and Associate Professor of Medicine at Harvard Medical School\, Dr. Wagner focuses on the treatment of patients with GIST and sarcoma\, and conducts laboratory research and clinical studies to identify new targets and treatments for these diseases. He received a PhD in Biochemistry and Molecular and an MD from the University of Chicago Pritzker School of Medicine. Dr. Wagner completed his Internship and Residency in Internal Medicine at Brigham and Women’s Hospital in Boston\, where he later served as Chief Medical Resident. He completed a fellowship in Hematology and Medical Oncology at Dana-Farber Cancer Institute\, Brigham and Women’s Hospital\, and Massachusetts General Hospital\, and then joined the Oncology Staff at Dana-Farber where he is currently a Senior Physician in the Department of Medical Oncology. \n\nHerbert H. Loong\, MBBS\, PDipMDPath\, MRCP(UK)\, FRCP Edin\, FHKCP\, FHKAM(Medicine)\nThe Chinese University of Hong Kong \nDr. Herbert H. Loong holds conjoint appointments of Clinical Associate Professor in the Department of Clinical Oncology and Deputy Medical Director of the Phase 1 Clinical Trials Centre of The Chinese University of Hong Kong. He is also the current and founding convenor of the Prince of Wales Hospital Adult Sarcoma Multidisciplinary Team. \nDr. Loong obtained his medical degree with a Distinction in Surgery from The University of Hong Kong in 2003. He has completed a Fellowship in Drug Development at Princess Margaret Cancer Centre in Toronto\, Canada with a special focus on Experimental Therapeutics. His clinical and research interests also include Sarcoma Medical Oncology\, Thoracic Oncology and Health Economics. \nDr. Loong is a recipient of the European Cancer Congress Fellowship Grant (2013)\, the American Society of Clinical Oncology (ASCO) Annual Meeting Merit Award (2014)\, the Hong Kong College of Physicians Young Investigators’ Award (2014). Nominated by patients and their caregivers\, Dr. Loong led the Lung Cancer Team at CUHK to be bestowed the IASLC Foundation Cancer Care Team Award in recognition for providing the best thoracic oncology care in “Asia & Rest of the World” in 2018. \nDr. Loong has served or continues to serve in various capacities in various professional international oncology bodies\, including the International Affairs Committee and the Asia-Pacific Regional Council of ASCO\, the Membership\, Education and Communications Committees of the IASLC. He has been elected as a Board Member of the Connective Tissue Oncology Society (CTOS) for 2022-2024. He is also a founding executive committee member of the newly formed Asia Pacific Oncology Drug Development Network (APODDC). He is also a Board Member in the specialty of Medical Oncology in the Hong Kong College of Physicians. In his appointment as a Registration Committee member of Pharmacy and Poisons Board of Hong Kong\, he helps oversee the registration of medicinal products and clinical trials in the territory. \nThank you to our 2022 LRG webinar sponsors:
URL:https://liferaftgroup.org/event/updates-asco-2022/
CATEGORIES:Events
ORGANIZER;CN="Sara Rothschild":MAILTO:srothschild@liferaftgroup.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20220504T120000
DTEND;TZID=America/New_York:20220504T130000
DTSTAMP:20260504T201330
CREATED:20220406T120523Z
LAST-MODIFIED:20220406T120523Z
UID:10000229-1651665600-1651669200@liferaftgroup.org
SUMMARY:Effects of Nutrition and the Gut Microbiome in GIST Patients
DESCRIPTION:May 4th\, 12-1pm ET \nThe Life Raft Group is partnering with Fundación GIST México to present “Effects of Nutrition and Gut Microbiome in GIST Patients” to GIST patients and caretakers on May 4th at 12pm ET. Ms. Berenice Carbajal-López is a doctoral student who holds a Master in Health Sciences with a thesis related to the use of technologies in the nutritional and psychological care of patients with GIST. During this virtual presentation\, Ms. Carbajal-López will describe the benefits of proper nutrition\, the relationship between nutrition and surgical procedures\, the link between the microbiome and cancer\, and exercise. \nREGISTERAbout our Presenter: \nMs. Berenice Carbajal-López is a doctoral student who holds a master’s degree in Health Sciences with a thesis related to the use of technologies in the nutritional and psychological care of patients with GIST. She has a diploma in Clinical Research and Biostatistics at the National Cancer Institute in Mexico. She has experience in health care of GIST patients\, as Patient Care Coordinator from 2014 to 2019 and as Global Director since 2020 at Fundación GIST México. Ms. Carbajal-López has also collaborated in drafting and review of research articles and book chapters in the area of Oncology\, with eight publications to date as main author and co-author in indexed journals and has participated in national and international congresses such as SMEO 2018\, ASCO 2019\, and ESMO-GI 2017\, 2018\, 2019\, 2020\, 2021\, and 2022. \nThank you to our 2022 LRG webinar sponsors:
URL:https://liferaftgroup.org/event/nutrition-gut-microbiome-in-gist-patients/
CATEGORIES:Events,Webcast
ORGANIZER;CN="Sara Rothschild":MAILTO:srothschild@liferaftgroup.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20220406T120000
DTEND;TZID=America/New_York:20220406T130000
DTSTAMP:20260504T201330
CREATED:20220224T171146Z
LAST-MODIFIED:20220303T154212Z
UID:10000208-1649246400-1649250000@liferaftgroup.org
SUMMARY:Be an Informed Patient\, Part 2: GIST
DESCRIPTION:Be an Informed Patient\, Part 2: Navigating GIST NCCN Guidelines\nIn Part Two of our “Be an Informed Patient” series\, The Life Raft Group invites all GIST patients and caregivers to register for our NCCN Webinar taking place on April 6th at 12:00 pm ET. The National Comprehensive Cancer Network (NCCN) creates guidelines for different diseases to guide physicians in their clinical practice. Dr. Margaret von Mehren serves as the Chair of the sarcoma NCCN guidelines and has been a valuable player along with her medical colleagues on the evolution of the GIST guidelines over the years. In this webinar\, Dr. von Mehren will educate GIST patients and caregivers about these guidelines and provide some case study examples of how guidelines fit into the rubric of patient care. The Life Raft Group will also share insights on real world experiences among the patient community with the guidelines. \nREGISTERAbout our presenters:\nMargaret von Mehren\, MD\nFox Chase Cancer Center \nDr. Margaret von Mehren is Chief of Division of Sarcoma Medical Oncology at Fox Chase Cancer Center. Her research interest focuses in developmental therapeutics for sarcomas and gastrointestinal stromal tumors. She has led investigator-initiated trials\, collaborated with other investigators\, sarcoma clinical trials group\, as well as industry sponsored studies in the testing of novel agents in these rare diseases. Collaboration with the Phase I program and basic scientists at Fox Chase Cancer Center and elsewhere is key to identifying potential novel agents which may have a therapeutic benefit in the treatment of sarcomas. Dr. von Mehren’s work in sarcoma therapeutic development informs her role as the Associate Director of Clinical Research\, in which she oversees the development of investigator initiated clinical trials\, the scientific review and prioritization process of trials as well as conduct of clinical trials at Fox Chase Cancer Center. \n\nDenisse Montoya\, MS\nSenior Director\, Data Mgmt. & Research\, The Life Raft Group \nMs. Montoya has a wealth of experience in clinical evaluation projects including development of protocols\, case report forms\, informed consent\, surveys\, tissue repositories\, and study initiation She is proficient in data management\, preparing research for publication\, drug development\, clinical trial protocols\, onco-pathological/genetical dissemination\, and formulating research premises. As the Senior Director of Data Management & Research\, Denisse is the principal investigator for study protocol design and strategy of Patient Reported Outcomes (PRO). She has expertise in the analysis\, reporting\, and dissemination of PRO data and present scientific work. \nShe leads a dedicated staff in both patient support and in the identification of data trends that may lead to actionable information that will help patients coping with Gastrointestinal Stromal Tumor. In addition\, she takes the lead in collaborative research initiatives\, including maintaining relationships with potential partners\, contributing ongoing data\, and supporting hypothesis generation with the goal of increasing patient survival and advancing GIST research. \nDenisse holds a Bachelor of Science degree in Biology from Rowan University\, and a Master of Science Degree in Biomedical Science from Fairleigh Dickinson University
URL:https://liferaftgroup.org/event/be-an-informed-patient-part-2-gist/
CATEGORIES:Events,Webcast
ORGANIZER;CN="Sara Rothschild":MAILTO:srothschild@liferaftgroup.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20220222T120000
DTEND;TZID=America/New_York:20220222T120000
DTSTAMP:20260504T201330
CREATED:20220202T155920Z
LAST-MODIFIED:20220203T134700Z
UID:10000204-1645531200-1645531200@liferaftgroup.org
SUMMARY:Be an Informed Patient
DESCRIPTION:Navigating Survivorship Care\nFebruary 22 at 12pm ET \nThe Life Raft Group invites cancer patients and survivors and their caregivers to register for a webinar taking place on February 22\, 2022. The National Comprehensive Cancer Network (NCCN) has created guidelines specifically for patients and caregivers to help them navigate survivorship care. During this webinar\, NCCN’s Dr. Crystal Denlinger and Dottie Shead will review general principles of appropriate survivorship care and how to access and understand patient guidelines related to survivorship care\, so that all can ensure they are getting the appropriate care as cancer survivors. \nREGISTERAbout the Presenters\n\nDr. Crystal Denlinger\nSenior Vice President\, National Comprehensive Cancer Network \nCrystal Denlinger joined the National Comprehensive Cancer Network® (NCCN®) as Senior Vice President\, Chief Scientific Officer in April 2021. She oversees NCCN’s Oncology Research Program and the Drugs & Biologics and Biomarkers Compendia\, and provides\ninput into NCCN’s other programs. Prior to joining NCCN\, Dr. Denlinger was an Associate Professor of Hematology/Oncology at Fox Chase Cancer Center. In this capacity\, she served as the Chief of Gastrointestinal Medical Oncology where she managed the program’s clinical and research efforts\, the Deputy Director of the Early Phase Drug Development Program\, and Co-Director of the Survivorship Program. \nDr. Denlinger is a graduate of Rutgers New Jersey Medical School and The College of New Jersey\, where she earned her medical degree and bachelors of science. She completed her internal medicine residency at Mount Sinai Medical Center in New York City and her fellowship in hematology/oncology at Fox Chase Cancer Center/Temple University Hospital in Philadelphia. She is board certified in Internal Medicine and Medical Oncology. \nDr. Denlinger is a Fellow of the American College of Physicians (ACP) and a member of several medical societies\, including the American Society of Clinical Oncology (ASCO) and the European Society of Medical Oncology (ESMO). She has an extensive lecture and publication history\, with clinical and research interests including gastrointestinal cancers\, early phase drug development\, and cancer survivorship. \n\n\nDottie Shead\nSenior Director of Patient Information\, National Comprehensive Cancer Network \nIn this role\, Ms. Shead is responsible for production of the NCCN Guidelines for Patients. She monitors and maintains tracking schedules representing the status of the NCCN Guidelines for Patients in the development process and web publication. In addition\, Ms. Shead oversees the production of NCCN Programs affiliated with the NCCN Guidelines for Patients\, including the NCCN Know What Your Doctors Know Webinar series and NCCN Animations for Patients. \nMs. Shead joined NCCN in 2000 and served as a Guideline Coordinator responsible for the development\, update and publication of assigned NCCN Clinical Practice Guidelines. Dottie has a Master’s degree in Health Administration from St. Joseph’s University\, and a B.S. in Biology from Arcadia University.
URL:https://liferaftgroup.org/event/be-an-informed-patient-navigating-survivorship-care/
CATEGORIES:Education,Events
ATTACH;FMTTYPE=image/png:https://liferaftgroup.org/wp-content/uploads/2022/02/NCCN.png
ORGANIZER;CN="Sara Rothschild":MAILTO:srothschild@liferaftgroup.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20220106T120000
DTEND;TZID=America/New_York:20220106T130000
DTSTAMP:20260504T201330
CREATED:20211217T160325Z
LAST-MODIFIED:20220106T144522Z
UID:10000178-1641470400-1641474000@liferaftgroup.org
SUMMARY:The Value of Biomarker Testing: Case Studies
DESCRIPTION:Case Studies Across Multiple Institutions\nUnderstanding the role of mutations and biomarker testing in GIST is one of most important things that GIST patients need to learn. Knowing the driving force behind each individual’s tumors is not just important\, it is critical. In this webinar\, you will hear case study presentations from three top sarcoma institutions that demonstrate the value of biomarker testing. A Question & Answer session will follow the presentations. \nREGISTERPresenters:\nPrapassorn Thirasastr\, MD\, MSc\nPost doctorate Fellow\nSarcoma Medical Oncology Department\nThe University of Texas MD Anderson Cancer Center\, Texas \nDr. Thirasastr graduated from faculty of medicine\, Chulalongkorn University in Bangkok\, Thailand. She had trained at King Chulalongkorn Memorial Hospital\, Bangkok\, Thailand for 6 years and received board certification in both Internal Medicine and Medical Oncology. Also\, she had awarded a Higher Graduate Diploma of Clinical Sciences and Master of Sciences degree from Chulalongkorn University in 2016 and 2018\, respectively. Dr. Thirasastr had practiced as a medical oncologist in Thailand for 2 years before joining post-doctoral research program in MD Anderson Cancer Center under Dr. Neeta Somaiah\, an Associate Professor of Sarcoma Medical Oncology and Deputy Chair in Division of Cancer Medicine at University of Texas MD Anderson Cancer Center\, as her Mentor.Currently her researches focus on sarcoma\, especially liposarcoma\, and GISTs and she has engaged in both clinical and basic science research projects. \n\nSteven Bialick\, DO\nSylvester Comprehensive Cancer Center\, Miami \nSteve Bialick\, DO is a second-year hematology/oncology fellow at Jackson Memorial Hospital and the University of Miami/Sylvester Comprehensive Cancer Center in Miami\, FL.  He completed his internal medicine residency within the University of Pennsylvania Health System before working as a hematologic malignancy hospitalist at the Hospital of the University of Pennsylvania in Philadelphia\, PA.  He is now completing his oncology training with a focus on solid tumor malignancies\, specifically soft tissue and bone sarcomas.  His research interests include hereditary cancer predisposition syndromes\, circulating tumor DNA and its role in guiding targeted therapies\, and the role of DNA damage repair pathways in sarcomas. \n\nDr. Dixon Dorand\, MD\, PhD\nClinical Fellow\nVanderbilt University Medical Center \nDr. R. Dixon Dorand\, Jr.\, MD\, PhD completed his graduate studies at Case Western Reserve University in Cleveland\, OH. His research with Dr. Alex Huang\, MD\, PhD at Rainbow Babies and Children’s Hospital focused on understanding the mechanisms regulating immune therapy in adolescent and young adult cancers. Specifically\, he investigated the signaling pathways that alter gene expression involved in regulating responses to immune checkpoint therapy as well as the role of nanoparticles for drug delivery. After graduation\, he enrolled in the Physician Scientist Training Program at Vanderbilt University Medical Center where he completed his internal medicine residency training.   \nDr. Dorand is currently completing his medical oncology fellowship in the Molecular and Genetic Epidemiology of Cancer program at Vanderbilt Ingram Cancer Center (VICC). He works in the laboratory of Dr. Ben H. Park\, MD\, PhD where he uses a basic science approach to interrogate how mutations that regulate genetic machinery can be manipulated for therapeutic benefit. He also uses genetic profiling to determine which tumor mutations contribute to chemotherapy resistance in sarcomas. Clinically\, he collaborates with Dr. Elizabeth Davis\, MD & Dr. Vicki Keedy\, MD at VICC to characterize mutations in patient tumor samples in GIST and other sarcoma types that may provide new therapeutic targets. He hopes to pursue a career focused on GIST and other soft tissue & bone sarcomas once he completes his formal training. 
URL:https://liferaftgroup.org/event/biomarker-testing-case-studies/
CATEGORIES:Events
ORGANIZER;CN="Sara Rothschild":MAILTO:srothschild@liferaftgroup.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20211118T130000
DTEND;TZID=America/New_York:20211118T141500
DTSTAMP:20260504T201330
CREATED:20211013T191553Z
LAST-MODIFIED:20211101T192901Z
UID:10000174-1637240400-1637244900@liferaftgroup.org
SUMMARY:Immunotherapy and GIST
DESCRIPTION:As the landscape of GIST treatment continues to evolve\, the area of immunotherapy has grown interest. GIST contains tumor-infiltrating immune cells which opens the possibility to the rationale for immunotherapy treatments. This webinar will provide an overview of immunotherapy with some examples of studies exploring single agent versus combination of therapy in GIST. \n\nIf you have questions about this presentation\nor about registration\, please contact:\nSara Rothschild\, VP Program Services\, srothschild@liferaftgroup.org\nREGISTEROur Presenters\n\nJonathan Trent\, MD\nDirector\, Sarcoma Oncology\nSylvester Comprehensive Cancer Center\nMiami\, Florida \nDr. Trent is currently the Associate Director for Clinical Research\, the Director of the Bone and Soft-tissue Sarcoma Group at the Sylvester Comprehensive Cancer Center. Dr. Trent’s interests are in the clinical and translational research of sarcomas\, direct care of sarcoma patients\, and education about sarcoma. As Associate Director for Clinical Research\, his goal is to help Sylvester Faculty develop clinical trials that provide clinically effective and scientifically exciting therapy to cancer patients of South Florida and beyond. The major focus of his clinical\, educational and research efforts are with gastrointestinal stromal tumor (GIST)\, chondrosarcoma\, and other sarcomas. The major efforts of Dr. Trent’s research focus on understanding the mechanisms of action and resistance of imatinib in GIST and other sarcomas while striving toward improved therapeutic options. His work involves the use of novel preoperative/postoperative clinical trials\, prospectively acquired tumor tissue\, cell lines\, archival tissue\, as well as collaborations with disciplines such as the genomics facility\, surgical oncology\, pathology\, radiology and interventional radiology. \nJunaid Arshad\, MD\nAssistant Professor & Clinical Scholar\nUniversity of Arizona Cancer Center\nTucson\, Arizona\n \nDr. Arshad finished his medical degree from King Edward Medical University\, Lahore Pakistan. He relocated to the United States in 2013 and worked as a research volunteer at Wayne State University\, Detroit. After completing his internal medicine residency training from St. Mary’s Hospital Waterbury\, CT\, he moved to University of Miami for his hematology and medical oncology fellowship. \nDr. Arshad developed interest in Gastrointestinal Stromal Tumors (GIST) after working with Dr. Jonathan Trent who was also his mentor at the University of Miami. Dr. Arshad has published several peer reviewed publications focusing on the use of ctDNA in GIST. Currently Dr. Arshad is working as an Assistant Professor at University of Arizona Cancer Center in the field of GI Medical Oncology focusing on the GIST and Upper GI cancers. \nArun Singh\, MD\nOncologist\, Sarcoma and Connective Tissue Medical Oncology\nUniversity of California Los Angeles Medical Center\nSan Monica\, California\n \nDr. Singh is an associate professor in the Department of Medicine\, Division of Hematology/Oncology at the David Geffen School of Medicine UCLA. Dr Singh is a hematologist and medical oncologist whose practice focuses on the treatment of bone and soft tissue sarcomas. Dr Singh’s research focus is on developing novel therapies for patients with sarcomas. In the preclinical setting\, he works on elucidating the mechanisms contributing to the promotion of growth in cancer cells and optimizing the use of targeted therapy in specific sarcoma subtypes. The insights gained from these efforts are then translated into the clinic in the form of new drugs in early stage phase 1 and 2 clinical trials for sarcomas where there is an unmet clinical need. \nRonald DeMatteo\, MD\, FACS\nSurgeon\, Endocrinology and Oncology\nPenn Medicine\nPhiladelphia\, Pennsylvania \nDr. DeMatteo is the Chairman of the Department of Surgery and a Surgical Oncologist who specializes in treating diseases of the liver\, bile duct\, gallbladder\, pancreas and abdominal sarcomas (GIST). His clinical research has focused on liver\, bile duct\, gallbladder\, and pancreas cancers. In addition\, he has led several national trials testing the benefit of imatinib mesylate (Gleevec) following surgery for gastrointestinal stromal tumor (GIST)\, a tumor that usually begins in the stomach or intestine. In the laboratory he and his colleagues study the immune environment of the liver and tumor immunology\, working to develop immune therapies to help prevent tumors from returning after surgery. \nThank you to our sponsors!
URL:https://liferaftgroup.org/event/immunotherapy-and-gist/
CATEGORIES:Events,Research
ORGANIZER;CN="Sara Rothschild":MAILTO:srothschild@liferaftgroup.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20211102T120000
DTEND;TZID=America/New_York:20211102T120000
DTSTAMP:20260504T201330
CREATED:20210930T145624Z
LAST-MODIFIED:20210930T145721Z
UID:10000172-1635854400-1635854400@liferaftgroup.org
SUMMARY:Caring for the Caregiver
DESCRIPTION:Caring for the Caregiver will focus on common challenges caregivers experience and how these challenges can often lead to burnout\, while also highlighting the impact of COVID-19. This webinar will provide caregivers with tools and ideas to help improve their physical and emotional wellbeing. To close\, caregivers will be given the opportunity to engage in a self-care practice that is quick enough to integrate into their routine. \nREGISTEROur Presenter\n\nAlyson Erardy\, LMSW\, Oncology Social Worker\nAlyson is an oncology social worker at CancerCare providing emotional and practical support services to people affected by cancer. During her time at CancerCare\, Alyson has developed a passion and expertise in working with the caregiver population by creating new workshops\, programs and groups to create a strong community.
URL:https://liferaftgroup.org/event/caring-for-the-caregiver/
CATEGORIES:Events,Webcast
ORGANIZER;CN="Sara Rothschild":MAILTO:srothschild@liferaftgroup.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20211028T130000
DTEND;TZID=America/New_York:20211028T130000
DTSTAMP:20260504T201330
CREATED:20210924T195501Z
LAST-MODIFIED:20211015T173919Z
UID:10000171-1635426000-1635426000@liferaftgroup.org
SUMMARY:Perspectives in Biomarker Testing
DESCRIPTION:Who Are the “Players” Involved in Biomarker Testing?\nHear Their Perspectives\nUnderstanding the role of mutations and biomarker testing in GIST is one of most important things that GIST patients need to learn. Knowing the driving force behind each individual’s tumors is not just important\, it is critical in determining the most effective treatment for your mutation. Whether it is a pathologist\, an oncologist\, or the laboratory doing the testing\, they each play a key role in the testing process. Learn from different perspectives and ask questions to this distinguished panel of experts. \n\nIf you have questions about this presentation\nor about registration\, please contact:\nSara Rothschild\, VP Program Services\, srothschild@liferaftgroup.org\nREGISTEROur Presenters\n\nJonathan Trent\, MD\, PhD\nDirector\, Sarcoma Oncology\nSylvester Comprehensive Cancer Center\nMiami\, Florida \nDr. Jonathan C. Trent is currently the Associate Director for Clinical Research\, the Director of the Bone and Soft-tissue Sarcoma Group at the Sylvester Comprehensive Cancer Center. Dr. Trent’s interests are in the clinical and translational research of sarcomas\, direct care of sarcoma patients\, and education about sarcoma. As Associate Director for Clinical Research\, his goal is to help Sylvester Faculty develop clinical trials that provide clinically effective and scientifically exciting therapy to cancer patients of South Florida and beyond. The major focus of his clinical\, educational and research efforts are with gastrointestinal stromal tumor (GIST)\, chondrosarcoma\, and other sarcomas. The major efforts of Dr. Trent’s research focus on understanding the mechanisms of action and resistance of imatinib in GIST and other sarcomas while striving toward improved therapeutic options. His work involves the use of novel preoperative/postoperative clinical trials\, prospectively acquired tumor tissue\, cell lines\, archival tissue\, as well as collaborations with disciplines such as the genomics facility\, surgical oncology\, pathology\, radiology and interventional radiology. \n\nLeylah Drusbosky\, PhD\nMedical Science Liaison\nGuardant Health\nTampa\, Florida \nLeylah Drusbosky received her PhD in molecular biology from the University of Florida and has expertise in next generation sequencing\, liquid biopsy\, precision medicine\, and translational research. She is a Medical Science Liaison at Guardant Health\, a company that leverages liquid biopsy to guide personalized treatments in patients with advanced cancer and has a passion for communicating the need for comprehensive genomic profiling to identify the best treatment approach based on each patient’s unique disease biology. \n\nKeith Killian\, PhD\nSenior Pathologist & Associate Medical Director\nFoundation Medicine\nCambridge\, Massachusetts \nDr. Killian is Senior Pathologist and Associate Medical Director at Foundation Medicine. He also serves as the lead pathologist on the partnership with Genentech to develop comprehensive gene expression profiling assays for clinical trial use. Notable prior translational medicine achievements include working with clinicians from the NIH Pediatric Gastrointestinal Stromal Tumor (GIST) clinic to discover the bimodal molecular pathologic mechanism of GIST tumorigenesis\, whereby reciprocal epigenetic and genetic inactivation of succinate dehydrogenase (SDH) explain SDH deficiency in KIT/kinase-WT GIST. Other recent work includes the methyl-deviation index (MDI) as a prognostic marker in breast cancer; MDI can be more generally used to measure malignant cellularity\, including lineage and purity\, in routine biopsies. We also recently discovered the remarkable convergence of epigenomic programming in pluripotent stem cells and germ-cell-tumor cells. Then\, we are completing a study of the clinical utility of saliva in the molecular profiling of solid and hematologic malignancy.\n\nThank you to our sponsors!
URL:https://liferaftgroup.org/event/perspectives-in-biomarker-testing/
CATEGORIES:Education,Events
ORGANIZER;CN="Sara Rothschild":MAILTO:srothschild@liferaftgroup.org
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211020
DTEND;VALUE=DATE:20211023
DTSTAMP:20260504T201330
CREATED:20210902T140123Z
LAST-MODIFIED:20211008T131333Z
UID:10000169-1634688000-1634947199@liferaftgroup.org
SUMMARY:New Horizons GIST Conference
DESCRIPTION:The New Horizons GIST conference will once again be held virtually\, due to the ongoing covid-19 pandemic\, and this year will welcome GIST advocates as well as patients & caregivers.\nNew Horizons GIST traditionally focuses on a large annual conference gathering over 50 representatives from 30 countries to discuss critical information about GIST that impacts the global GIST patient and medical communities. Participants have opportunities to interact with leading GIST experts\, learn new medical and scientific information about GIST\, exchange best practices and discuss advocacy issues. \nOn behalf of the NEW HORIZONS GIST Steering Committee\, the Life Raft Group is very pleased to invite you to the New Horizons GIST 2021 Conference from October 20-22\, 2021 via Zoom. \nThe theme is “Celebrating 20 Years of GIST Treatments.” Over the course of the three day conference\, we will travel along the 20-year treatment journey of GIST and look towards the future. Day one will be the Kickoff Celebration in which we discuss the birth of targeted medicine. Day Two will focus on current targeted therapies\, and Day Three will end with the future outlook and important research questions needing to be addressed by the global GIST community. Each day will have virtual sessions between 9:00 am to 12:00 pm Eastern Time. \nThis meeting will be a great opportunity to come together and reflect upon the past 20 years but also look towards the future as a global community. Each organization is welcome to register several representatives. \nIf you have any questions about this conference\, please email: srothschild@liferaftgroup.org \nREGISTERProposed Agenda: (updated 10.8.2021)\npdf here \nOctober 20 \n \nOctober 21 \n \nOctober 22 \n \nSee past New Horizon GIST conferences
URL:https://liferaftgroup.org/event/new-horizons-gist-conference/
CATEGORIES:Events,International
ATTACH;FMTTYPE=image/png:https://liferaftgroup.org/wp-content/uploads/2021/09/new-horizons-GIST-2021.png
ORGANIZER;CN="Sara Rothschild":MAILTO:srothschild@liferaftgroup.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210812T120000
DTEND;TZID=America/New_York:20210812T120000
DTSTAMP:20260504T201330
CREATED:20210720T175722Z
LAST-MODIFIED:20210721T142417Z
UID:10000168-1628769600-1628769600@liferaftgroup.org
SUMMARY:What GISTers Need to Know About Clinical Trials
DESCRIPTION:Clinical Trials 101\, a GISTory of Clinical Trials\, & How to Talk to Your Medical Team about Clinical Trials\nClinical trials are an essential tool of modern medicine. We have heard a lot about clinical trials of COVID-19 vaccines and therapies during the pandemic\, and most GISTers are aware that clinical trials established the effectiveness of drugs like imatinib. However\, beyond the headlines there’s a lot to consider when evaluating a clinical trial – especially if you are considering enrolling in one. Who designed the trial? Who approved it? Who is paying for it? Who decides which patients will be enrolled? How will the results be evaluated? And what’s the relationship between clinical trials and “real world evidence”? \nPlease join LRG Science Team members Jim Hughes and David Josephy for an informative presentation on the topic of clinical trials. \nREGISTERAbout the Presenters:\n\nDr. David Josephy \n\nDavid Josephy\, PhD.\nPresident of Life Raft Group Canada\nDavid Josephy was a Professor of Molecular and Cellular Biology at the University of Guelph in Ontario\, Canada\, until his recent retirement. He authored a textbook titled\, “Molecular Toxicology”\, and has written more than 100 scientific publications in biochemistry\, toxicology\, and cancer research.\n\nJim Hughes \nJim Hughes\nLife Raft Group Clinical Trials Coordinator\nJim Hughes attended Kenyon College and Loyola University\, Chicago where he earned a BA in Philosophy. Between schools Jim served three years as an enlisted man and officer in the United States Army in the US and Vietnam. Jim retired from the telecommunications industry after a 35-year career including positions in engineering\, long-range planning\, and marketing. Jim and Margi are the parents of two children Nancy and Jamie. Nancy Hughes Welsh (1967-2005) was an early member of The Life Raft Group (2002). Nancy was diagnosed with leiomyosarcoma in 1991 at age 23. After ten years of surgery and chemotherapy Nancy was re-diagnosed with GIST in 2001. Nancy participated in the Phase Three imatinib trial in 2001 and the Phase Two sunitinib trial in 2003. Jim and Margi continue to facilitate the LRG Chicago chapter meetings. Jim serves on the Board of the LRG and is a member of the LRG Science Team.
URL:https://liferaftgroup.org/event/what-gisters-need-to-know-about-clinical-trials/
CATEGORIES:Education,Events
ORGANIZER;CN="Sara Rothschild":MAILTO:srothschild@liferaftgroup.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210713T120000
DTEND;TZID=America/New_York:20210713T120000
DTSTAMP:20260504T201330
CREATED:20210601T193918Z
LAST-MODIFIED:20210601T200108Z
UID:10000142-1626177600-1626177600@liferaftgroup.org
SUMMARY:GIST Awareness Day - Live Q&A with SDH Experts
DESCRIPTION:Join us this GIST Awareness Day\, July 13th\, as our esteemed panel of GIST experts (from our Pediatric & SDH-Deficient GIST Consortium) answers your questions about SDH-deficient GIST. You can email your prepared questions to Sara Rothschild at srothschild@liferaftgroup.org or type them into the chat feature the day of the webinar. We will get to as many questions as possible during the event. \nREGISTER
URL:https://liferaftgroup.org/event/gist-awareness-day-live-qa-with-sdh-experts/
CATEGORIES:Education,Events
ATTACH;FMTTYPE=image/png:https://liferaftgroup.org/wp-content/uploads/2021/06/gist-awareness-day-panel-2021.png
ORGANIZER;CN="Sara Rothschild":MAILTO:srothschild@liferaftgroup.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210524T120000
DTEND;TZID=America/New_York:20210524T120000
DTSTAMP:20260504T201330
CREATED:20210505T192910Z
LAST-MODIFIED:20210524T171308Z
UID:10000140-1621857600-1621857600@liferaftgroup.org
SUMMARY:New Treatment Updates for Advanced GIST
DESCRIPTION:During this webinar\, Dr. William Tap will discuss newly approved treatment options as well as clinical trials for advanced GIST. Dr. Tap will explain how each of these drugs works to target mutations and when they are used for targeted treatment. A Q&A session will follow this presentation. \nREGISTERAbout the Presenter\nDr. William D. Tap\nChief\, Sarcoma Medical Oncology Service\nMemorial Sloan Kettering Cancer Center \nDr. Tap is the Chief of the Sarcoma Medical Oncology Service at Memorial Sloan Kettering Cancer Center in New York. Bill has extensive experience in translational medicine and is currently in charge of the clinical\, basic science\, and translational aspects of the Sarcoma Medical Oncology Program at MSKCC. He is also helping to develop a comprehensive Adolescent and Young Adult Caner Program at MSKCC. Bill received his Medical Degree from Jefferson Medical College in Philadelphia\, PA and performed his residency in Internal Medicine at the Vanderbilt University Medical Center in Nashville\, TN and his fellowship in Hematology and Medical Oncology at the UCLA Medical Center in Los Angeles\, CA. Bill also has a tremendous interest in global health care initiatives and effecting health disparities in underserved areas in the US and abroad.
URL:https://liferaftgroup.org/event/new-treatment-updates-for-advanced-gist/
CATEGORIES:Events
ORGANIZER;CN="Sara Rothschild":MAILTO:srothschild@liferaftgroup.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210512T120000
DTEND;TZID=America/New_York:20210512T130000
DTSTAMP:20260504T201330
CREATED:20210420T151025Z
LAST-MODIFIED:20210420T151025Z
UID:10000138-1620820800-1620824400@liferaftgroup.org
SUMMARY:Management of Metastatic GIST
DESCRIPTION:What to Expect When a Tumor Has Spread\nWhile surgery is the backbone of treatment for localized GIST\, in the context of metastatic disease\, treatment generally relies on medical therapy with tyrosine kinase inhibitors such as imatinib. Surgery is used predominantly to optimize their efficacy. This webinar will review options for therapy when patients are diagnosed with metastatic disease at the time of their initial diagnosis\, during observation after initial resection of a GIST\, and when metastatic GIST is resistant to imatinib. We will discuss the role that mutational status and drug toxicities may play in determining the optimal therapy for individual patients. \nREGISTERAbout the Presenter:\nDr. Aimee Crago\, Surgical Oncologist\nMemorial Sloan Kettering Cancer Center \nDr. Crago earned her PhD at the University of Cambridge as a British Marshall Scholar and her MD in the Harvard-MIT Division of Health Sciences and Technology before training in surgery and surgical oncology at Georgetown University Medical Center and Memorial Sloan Kettering Cancer Center. She joined the MSKCC faculty in 2010 as member of the Gastric and Mixed Tumor Service and the Sarcoma Disease Management Team\, and now serves as Associate Attending Surgeon. She is an active participant in the care of patients with soft tissue sarcoma\, GIST and desmoid-type fibromatosis and coordinates a translational science research program that focuses on understanding the molecular drivers of sarcomas and how genomic aberrations in these tumors can inform patient care. Her work has been funded by the National Cancer Institute\, the Food and Drug Administration\, the American Society of Clinical Oncology\, the American College of Surgeons\, and the American Cancer Society among others. Dr. Crago is committed to educating others regarding sarcoma biology and patient care; as such\, she trains clinical and research fellows at Memorial Sloan Kettering\, is a Gerstner Sloan Kettering Graduate School Special Contributing Faculty Member\, and works as chair of the Society for Surgical Oncology Sarcoma Disease Site Working Group.   
URL:https://liferaftgroup.org/event/management-of-metastatic-gist/
CATEGORIES:Education,Events
ORGANIZER;CN="Sara Rothschild":MAILTO:srothschild@liferaftgroup.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210429T120000
DTEND;TZID=America/New_York:20210429T130000
DTSTAMP:20260504T201330
CREATED:20210408T134459Z
LAST-MODIFIED:20210408T134855Z
UID:10000137-1619697600-1619701200@liferaftgroup.org
SUMMARY:Genetics of GIST
DESCRIPTION:Risks\, Management\, and What to Know for You and Your Family\nIn this webinar\, we will review what is known about the hereditary causes behind GISTs\, current genetic testing options and results\, how this information affects screening and management\, and implications for one’s family. \n\nREGISTER\n \nPresenters:\nLindsay Kipnis received her MS in Genetic Counseling from Brandeis University in 2013. After graduating she worked in oncology at Women & Infants Hospital in Rhode Island. She joined the Center for Cancer Genetics and Prevention at DFCI in 2014. Lindsay is focused on ensuring that all ovarian cancer patients receive the genetic counseling and testing that is recommended. She also sees a variety of adult patients with personal and family histories of cancer. \n\n \nBecca Vanderwall is a licensed and certified genetic counselor currently practicing at Dana-Farber Cancer Institute in the pediatric cancer genetics risk program. She previously worked in neurometabolics and mitochondrial disease at Boston Children’s Hospital. She earned her MS in Genetic Counseling and MPH in Public Health Genetics from the University of Pittsburgh in 2016. Her special interests include public health research and policy\, health disparities and equity\, hereditary brain tumor risk\, and family dynamics and communication.
URL:https://liferaftgroup.org/event/genetics-of-gist/
CATEGORIES:Events
ORGANIZER;CN="Sara Rothschild":MAILTO:srothschild@liferaftgroup.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210224T120000
DTEND;TZID=America/New_York:20210224T120000
DTSTAMP:20260504T201330
CREATED:20210203T201450Z
LAST-MODIFIED:20210208T141853Z
UID:10000132-1614168000-1614168000@liferaftgroup.org
SUMMARY:Finding Biomarkers that Cause GIST
DESCRIPTION:From Research to Clinical Application\nEvery GIST patient is unique based on their biology and what treatment to which they will potentially respond. \nDr. Lori Rink\, Fox Chase Cancer Center\, and Dr. Inga-Marie Schaefer\, Brigham & Women’s Hospital\, are two researchers who are making discoveries in their respective laboratories to uncover the unique biomarkers in GIST that will be future drug targets. \nDr. Margaret von Mehren\, Fox Chase Cancer Center\, will moderate the webinar and help the audience understand why these important discoveries in the lab are important to clinicians. This concept of translational medicine is an important field as it helps bring advances into the clinic that can directly impact the survival of GIST patients. \nREGISTERAbout the Presenters\nLori Rink\, PhD\nAssistant Professor\, Molecular Therapeutics\, Fox Chase Cancer Center. Dr. Rink studied at the Biology at the University of Scranton  and  received her doctorate in  for a Doctorate in Molecular Biology from Temple University followed by a post-doctoral fellowship at Fox Chase Cancer Center.  She is an Assistant Professor in the Molecular Therapeutic program. Along with Dr. von Mehren\, two graduate students\, and a post-doctoral fellow\, Dr. Rink’s lab is dedicated to investigating why some GIST patients eventually develop a resistance to Gleevec\, discovering combinations of drugs that will attack GIST\, and identifying markers that could predict how patients will respond to Gleevec. \nInga-Marie Schaefer\, MD\nAssociate Pathologist\, Brigham & Women’s Hospital\, Instructor in Pathology\, Harvard Medical School\nDr. Schaefer is an instructor at the Department of Pathology at Brigham and Women’s Hospital\, Harvard Medical School in Boston\, MA. After graduating with an M.D. degree from Georg-August-University Goettingen in Germany\, she trained in Anatomic Pathology in Germany and at Brigham and Women’s Hospital. Her post-doctoral research in Dr. Jonathan Fletcher’s translational sarcoma laboratory focused on characterizing mechanisms of genomic progression in GIST/sarcoma\, combining diagnostics\, biology\, and genetics. Dr. Schaefer is now evaluating mechanisms of incremental cell cycle dysregulation in GIST progression. \n\nAbout the Moderator\nMargaret von Mehren\, MD\nAssociate Professor\, Director of Sarcoma\, Fox Chase Cancer Center\nDr. von Mehren matriculated at Georgetown University in Washington\, DC\, where she majored in Biology and minored in Philosophy\, and graduating in 1985 with honors. She received her medical degree from Albany Medical College in Albany\, NY. Dr. von Mehren completed an internship and residency at New York University Medical Center in New York before moving to Philadelphia for her fellowship in medical oncology at the Fox Chase Cancer Center and Temple University. After completing fellowship\, Dr. von Mehren joined the faculty of the department of Medical Oncology at Fox Chase Cancer Center where she remains today as and Associate Professor and the director of the Sarcoma program. She is a member of the NCCN panel for soft tissue sarcomas and GIST task force\, as well as the Intergroup GIST Task force. She also volunteers at the NIH Pediatric Wildtype GIST clinic biannually.
URL:https://liferaftgroup.org/event/finding-biomarkers-that-cause-gist/
CATEGORIES:Education,Events
ORGANIZER;CN="Sara Rothschild":MAILTO:srothschild@liferaftgroup.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210211T120000
DTEND;TZID=America/New_York:20210211T120000
DTSTAMP:20260504T201330
CREATED:20201103T133157Z
LAST-MODIFIED:20210124T180346Z
UID:10000093-1613044800-1613044800@liferaftgroup.org
SUMMARY:LRG Webcast Series: hPPGL Syndrome - a Misnomer with Consequences
DESCRIPTION:Dr. Annes will review the hPPGL Syndrome with particular focus on the underlying genetics basis and related tumor risks. He will review the benefits/limitations of genetic testing and pre-symptomatic screening\, including his personal experience directing Stanford’s Hereditary Neuroendocrine Neoplasia Clinic. Finally\, he will discuss opportunities for advancing hPPGL care and ongoing research. \nREGISTERPresenter:\nJustin Annes\, MD\, PhD\nAssociate Professor\, Stanford Department of Medicine \nDr. Annes is an Associate Professor in Stanford’s Department of Medicine and a Faculty Fellow in Stanford’s Chemistry\, Engineering & Medicine for Human Health Institute (ChEM-H). He obtained his BS from Haverford College (1996)\, MD PHD from New York University (1996) and trained in Internal Medicine\, Clinical Genetics and Chemical Biology at Brigham and Women’s Hospital / Harvard University (2011). Dr. Annes is director and founder of Stanford’s Hereditary Neuroendocrine Tumor Clinic (2012) which focuses on the longitudinal care of patients and families with inherited endocrine tumor syndromes\, primarily hPPGL\, MEN1 and MEN2. He participates in several neuroendocrine-focused patient advocacy / research foundations including The Pheo Para Alliance\, Neuroendocrine Tumor Research Foundation and the NIH Pediatric Wildtype GIST Clinic. His NIH-funded research program is positioned at the interface of endocrine pathophysiology\, synthetic chemistry and hereditary disease. The organizing principle of his research program is to harness the power of chemistry\, human tissue samples and animal disease models to deliver fundamental biologic insights and develop novel therapeutic leads for the treatment of endocrine disorders.
URL:https://liferaftgroup.org/event/lrg-webcast-hppgl-syndrome/
CATEGORIES:Education,Events
ATTACH;FMTTYPE=image/jpeg:https://liferaftgroup.org/wp-content/uploads/2020/11/annes1.jpg
ORGANIZER;CN="Sara Rothschild":MAILTO:srothschild@liferaftgroup.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Australia/Melbourne:20210205T110000
DTEND;TZID=Australia/Melbourne:20210205T110000
DTSTAMP:20260504T201330
CREATED:20210111T201224Z
LAST-MODIFIED:20210113T134856Z
UID:10000094-1612522800-1612522800@liferaftgroup.org
SUMMARY:Australian GISTers Virtual Meet & Greet
DESCRIPTION:Please be aware of the time difference: This webinar takes place on Feb 4th at 7pm ET for the US and Feb 5th at 11 am Melbourne time.) \nPlease join us for a Virtual Meet & Greet with our new Australian GIST Representatives Shari Reid and Amy Kenworthy! GIST patients and family members are welcome to join this virtual get together to connect as well as meet one of the leading GIST experts in Australia – Dr. John Zalcberg from Monash University. \nREGISTERPresenters\nShari Reid\, Victoria \nShari Reid\, formerly a Systems Administrator in Health & Safety\, is currently a proud\, full-time mum to son Robbie. Though she’s living in regional Victoria with her husband\, Glenn\, and son\, Shari was born in the U.S. and her family moved to Australia when she was a baby. \n\nAmy Kenworthy\, Gold Coast \nProfessor Amy Kenworthy\, also born in the U.S.\, was raised in Massachusetts and immigrated to Queensland\, Australia\, after finishing her PhD in 1999. She and her husband\, George\, are both professors at Bond University on the Gold Coast. They have two teens\, Bryce\, 13\, and Mariel\, 17. \n\nRead more about these amazing GISTers! \n\nDr. John  Zalcberg\nProfessor Zalcberg is currently the Head of the Cancer Research Program as well as NHMRC (MRFF) Practitioner Fellow in the School of Public Health and Preventive Medicine at Monash University – currently overseeing the establishment and activities of clinical quality registries across various tumour types. He is also the inaugural Tony Charlton Chair of Oncology at Alfred Health as well.\nYou can view this presentation on OncLive – Dr. Zalcberg on the Management of Patients With GIST
URL:https://liferaftgroup.org/event/australian-gisters-virtual-meet-greet/
CATEGORIES:Events,International
ORGANIZER;CN="Sara Rothschild":MAILTO:srothschild@liferaftgroup.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20201026T120000
DTEND;TZID=America/New_York:20201026T120000
DTSTAMP:20260504T201330
CREATED:20201002T183013Z
LAST-MODIFIED:20201022T161543Z
UID:10000089-1603713600-1603713600@liferaftgroup.org
SUMMARY:Women in Sarcoma: Case Presentations
DESCRIPTION:Case Presentations\nOctober 26\, 12PM ET \nPlease join us for the second webcast of our Women in Sarcoma series. The Life Raft Group has developed the Women in Sarcoma program in recognition of the many women sarcoma specialists that engage with the sarcoma patient community and focus on educating and advocating on behalf of those living with sarcoma. \nThis panel features three women sarcoma experts presenting unique case studies that they have encountered in their practices. Panelists will interact with each other about these case studies\, and participants will gain meaningful insight into how these experts diagnose and treat sarcoma patients\, and how they collaborate with colleagues toward the goal of achieving positive outcomes for these challenging cases. \n\nIf you have questions about this panel or about registration\, please contact Sara Rothschild\, VP Program Services \n\nPlease join us for this interactive session with women leading the field of sarcoma!\n\nREGISTEROur Panel of Experts\n \n\nVaia Florou\, MD\nOncologist\nUniversity of Utah\nHuntsman Cancer Center\n \n\nCiara Kelly\, MBBCh BAO\nOncologist\nMemorial Sloan Kettering\nCancer Center\n \n\n\nSandra R. Brackert\, NP\nNurse Practitioner\nRonald Reagan UCLA\nMedical Center
URL:https://liferaftgroup.org/event/women-in-sarcoma-case-presentations/
CATEGORIES:Education,Research,Webcast
ATTACH;FMTTYPE=image/jpeg:https://liferaftgroup.org/wp-content/uploads/2020/10/Women-In-Sarcoma-2.jpg
ORGANIZER;CN="Sara Rothschild":MAILTO:srothschild@liferaftgroup.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20201020T120000
DTEND;TZID=America/New_York:20201020T120000
DTSTAMP:20260504T201330
CREATED:20200909T152729Z
LAST-MODIFIED:20200916T162445Z
UID:10000087-1603195200-1603195200@liferaftgroup.org
SUMMARY:LRG Webcast: Genetics 101
DESCRIPTION:With the alphabet soup of terms and genes that cancer patients tend to hear during diagnosis\, it takes some time to really understand what these terms mean. \nIn her Genetics 101 webcast\, Dr. Raygada will unravel the DNA terms and seek to empower patients by helping them understand the genetic basis of their conditions so that they may decrease the risks associated with the mutations and tumors they carry. \nREGISTERAbout the presenter\nMargarita Raygada\, PhD\, Oncology Genetic Counselor \nDr. Raygada’s doctorate degree is in Medical Science from the Uniformed Services University of the Health Sciences/Naval Hospital\, Bethesda\, Maryland. Her Master’s degree is in Human Genetics and Genetic Counseling\, Georgetown University Hospital (GUH) in Washington\, D.C.\, with two post-doctoral fellowships: Molecular Biology at The Johns Hopkins Hospital in Baltimore\, and Cancer Genetics at GUH. Research Focus: Cancer genetics is my passion. I am interested in delineating the genetic changes in rare tumors and identifying associated phenotypes that may lead to common pathways and therefore improved outcomes for cancer patients. But most importantly I hope to empower patients by helping them understand the genetic basis of their conditions\, and by educating them on how they can use this information to manage their cancer so that they may decrease the risks associated with the mutations and tumors they carry.
URL:https://liferaftgroup.org/event/lrg-webcast-genetics-101/
CATEGORIES:Education,Webcast
ATTACH;FMTTYPE=image/jpeg:https://liferaftgroup.org/wp-content/uploads/2020/08/raygada-event.jpg
ORGANIZER;CN="Sara Rothschild":MAILTO:srothschild@liferaftgroup.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200924T140000
DTEND;TZID=America/New_York:20200924T140000
DTSTAMP:20260504T201330
CREATED:20200911T003207Z
LAST-MODIFIED:20200911T122756Z
UID:10000088-1600956000-1600956000@liferaftgroup.org
SUMMARY:Women in Sarcoma: Cancer Warriors
DESCRIPTION:An Interactive Multidisciplinary Panel of Experts\nSeptember 24th\, 2020 at 2pm \nThe Life Raft Group has developed the Women in Sarcoma program in recognition of the many women sarcoma specialists that engage with our organization and our patient and caregiver community to educate and advocate on behalf of those living with sarcoma. Our goal is to highlight women in the sarcoma medical profession that make a difference in patients’ lives\, and to inspire the community to hear stories and perspectives of women’s role in oncology. \nThe September webcast will feature an interactive panel of women sarcoma experts sharing their expertise as powerful advocates working on behalf of those living with sarcoma. Please join us for this interactive session with women leading the field of sarcoma! \nIf you have questions about this panel or about registration\, please contact Sara Rothschild\, VP Program Services \n\nREGISTEROur Panel of Experts\n[table “61” not found /]
URL:https://liferaftgroup.org/event/women-in-sarcoma-cancer-warriors/
CATEGORIES:Events
ORGANIZER;CN="Sara Rothschild":MAILTO:srothschild@liferaftgroup.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200616T120000
DTEND;TZID=America/New_York:20200616T130000
DTSTAMP:20260504T201330
CREATED:20200512T205723Z
LAST-MODIFIED:20200515T142935Z
UID:10000066-1592308800-1592312400@liferaftgroup.org
SUMMARY:LRG Webcast Series: GIST: How to Understand your Pathology Report
DESCRIPTION:In this webinar\, we will be discussing how to interpret your pathology report. We will cover interpretation of all parts of a pathology report\, beginning with understanding the final diagnosis and diagnostic comment. We will then review the results and significance of performed ancillary testing\, including immunohistochemistry\, prognostic biomarker testing\, and molecular testing. We will end by discussing how the aforementioned pathology report data affects clinical surgical and therapeutic decision-making. \nREGISTERAbout the Presenters:\nKelsey McHugh\, M.D.\nGastrointestinal\, Hepatic\, and Pancreatobiliary Pathology Fellow\nRobert J. Tomsich Pathology & Laboratory Medicine Institute\nCleveland Clinic \nKelsey McHugh\, MD is a board certified anatomic and clinical pathologist\, with cytopathology subspecialty certification\, who is currently completing gastrointestinal\, hepatic\, and pancreatobiliary pathology subspecialty training. She anticipates graduating from the Cleveland Clinic Gastrointestinal\, Hepatic\, and Pancreatobiliary Pathology Fellowship in June 2020\, after which she will remain at the Cleveland Clinic as a staff pathologist beginning July 2020.
URL:https://liferaftgroup.org/event/understand-your-pathology-report/
CATEGORIES:Education,Webcast
ORGANIZER;CN="Sara Rothschild":MAILTO:srothschild@liferaftgroup.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200514T140000
DTEND;TZID=America/New_York:20200514T150000
DTSTAMP:20260504T201330
CREATED:20200421T143006Z
LAST-MODIFIED:20200520T122214Z
UID:10000061-1589464800-1589468400@liferaftgroup.org
SUMMARY:LRG Webcast Series: GIST\, TKI Treatment & Effects on Memory
DESCRIPTION:Cancer-related cognitive impairment\, or CRCI\, is common among certain cancer survivors\, for example\, individuals with breast cancer. CRCI usually presents as mild to moderate problems with memory and attention and can even persist long after cancer treatment has ended. Many have called this “chemobrain” or “chemofog” but research over the past three decades indicates that cancer itself\, genetic vulnerabilities and treatments other than chemotherapy can lead to persistent CRCI. \nSimilar to patients treated with chemotherapy\, patients with GIST are complaining about long-term side effects of Gleevec therapy with respect to cognitive function (“Gleevec brain”). Nevertheless\, very little is known about CRCI in cancer patients who are being treated with tyrosine kinase inhibitors (TKIs)\, like Gleevec\, including patients with GIST. \nThis discussion will review CRCI in general\, and how a person who is being treated for GIST could be affected. We will also talk about strategies that can help ameliorate CRCI and discuss our new research on CRCI and GIST. Finally\, in light of the COVID-19 pandemic\, we will give advice on how cancer survivors can best cope with and care for themselves during this unusual global health event. \nSEE The RecapAbout the Presenters:\nAnette Duensing\, M.D.\nAssociate Professor of Pathology\nUniversity of Pittsburgh School of Medicine \nAnette Duensing holds an M.D. degree from the University of Hannover School of Medicine\, Germany\, and is an Associate Professor of Pathology at the University of Pittsburgh School of Medicine as well as Member of the Cancer Therapeutics Program at the UPMC Hillman Cancer Center. Her research focuses on gastrointestinal stromal tumors (GISTs) as well as other sarcomas with the goal of identifying novel therapeutic approaches. Recently\, Dr. Duensing has teamed up with Dr. Robert Ferguson at UPMC HCC to study cognitive impairment in GIST patients treated with Gleevec and other tyrosine kinase inhibitors. Dr. Duensing is the author of nearly 70 original articles\, reviews and book chapters. Her research has been supported by the American Cancer Society\, the Sarcoma Foundation of America\, the GIST Cancer Research Fund and the Life Raft Group. \nRobert J. Ferguson\, Ph.D.\nAssistant Professor of Medicine with the Division of Hematology/Oncology\nUniversity of Pittsburgh School of Medicine and Hillman Cancer Center \nDr. Ferguson is a clinical psychologist and Assistant Professor of Medicine with the Division of Hematology/Oncology at the University of Pittsburgh School of Medicine and Hillman Cancer Center. His clinical and research interests are the treatment of cognitive effects of cancer\, cancer survivorship and palliative care. He is the author of numerous peer reviewed research articles and book chapters on treatment of cancer-related cognitive dysfunction and other topics related to the field of behavioral medicine. His research has been funded by grants from the National Cancer Institute\, NIH Office of Research on Women’s Health\, and the Lance Armstrong Foundation. \n\n \nDisclaimer:\nWe cannot provide individual medical advice during this webcast. Information provided in this webcast is not intended as a substitute for your physician’s guidance and care.
URL:https://liferaftgroup.org/event/lrg-webcast-series-treatment-effects-memory/
CATEGORIES:Education,Events
ORGANIZER;CN="Sara Rothschild":MAILTO:srothschild@liferaftgroup.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200323T120000
DTEND;TZID=America/New_York:20200323T130000
DTSTAMP:20260504T201330
CREATED:20200311T125440Z
LAST-MODIFIED:20200414T152639Z
UID:10000057-1584964800-1584968400@liferaftgroup.org
SUMMARY:LRG Webcast Series: New Treatment Options for Advanced GIST & Concerns about the Coronavirus
DESCRIPTION:Avapritinib is a medication used for the treatment of tumors due to one specific rare mutation: It is specifically intended for adults with unresectable or metastatic gastrointestinal stromal tumor that harbor a platelet-derived growth factor receptor alpha exon 18 mutation. \nRipretinib is an investigational broad-spectrum KIT and PDGFRα inhibitor in development for the treatment of patients with advanced gastrointestinal stromal tumors (GIST). \nDuring this webcast presentation\, Dr. Michael Heinrich will discuss these two new treatment options for advanced GIST. Dr. Heinrich will explain how each of these drugs works to target mutations for which there has previously been no targeted treatment. He will also address key questions for GIST patients concerning the coronavirus. \nListen to the recapAbout the Presenter:\n \nMichael Heinrich\, M.D.\nProfessor of Medicine and Cell/Developmental Biology\nOHSU School of Medicine \nDr. Heinrich earned his medical degree from Johns Hopkins School of Medicine in Baltimore and completed both his residency training and fellowship in hematology/medical oncology at OHSU. \nDr. Heinrich’s research\, like much of the work at the Knight Cancer Institute\, revolves around a basic\, yet complex premise. You have to understand what is broken in order to fix it. That’s why Dr. Heinrich is intently focused on identifying the molecular targets that cause cancer\, which is essential to the development of better and less toxic therapies. He is recognized internationally for groundbreaking research discoveries that have improved care for patients with gastrointestinal stromal tumors\, and his research has implications for many types of cancer. \n\nDisclaimer:\nWe cannot provide individual medical advice during this webcast. Information provided in this webcast is not intended as a substitute for your physician’s guidance and care.
URL:https://liferaftgroup.org/event/lrg-webcast-series-new-treatment-options-for-advanced-gist/
ATTACH;FMTTYPE=image/png:https://liferaftgroup.org/wp-content/uploads/2020/03/heinrich-event-v2.png
ORGANIZER;CN="Sara Rothschild":MAILTO:srothschild@liferaftgroup.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20190911T140000
DTEND;TZID=America/New_York:20190911T150000
DTSTAMP:20260504T201330
CREATED:20190725T201333Z
LAST-MODIFIED:20190917T152156Z
UID:10000037-1568210400-1568214000@liferaftgroup.org
SUMMARY:LRG Webcast Series: Updates on the Temozolomide Trial
DESCRIPTION:The Temozolomide Trial for SDH-deficient GIST Patients\nGIST is becoming increasingly diverse. SDH-deficient GIST and paragangliomas often occur in adolescents and young adults. Since these SDH mutations are germline\, multiple generations of family members are affected.\n\nDr. Jason Sicklick of Moores Cancer Center at the University of California San Diego will present a webcast detailing the Phase II study of Temozolomide (TMZ) in advanced SDH-mutant/deficient GIST\, a new study available to patients with SDH-deficient GIST.\n\n\nListen to the Webinar\n\nAbout the Presenter:\nJason K. Sicklick\, MD\, FACS\, is an Associate Professor of Surgery\, Division of Surgical Oncology; and Co-Director\, Biorepository and Tissue Technology Shared Resource\, Moores Cancer Center at the University of California\, San Diego\, UC San Diego Health Sciences. \n  \n  \n  \n\nTechnical Tips to Join Meeting:\n\nThis is a web-only meeting\, accessed only by your internet connection. Participants are encouraged to use the web link automatically provided after registration and to use computer speakers (and/or headsets if available) to hear the audio portion of the meeting. Please log in at least ten minutes prior to the start of the webinar.\nPlease ensure you have an updated version of Adobe Flash Player (Google Chrome has Flash built-in).\nIf you are using a mobile device or tablet\, in order to view and hear the conference\, download the ReadyTalk App from your App store.\n\n\nDisclaimer:\nWe cannot provide individual medical advice during this webcast. Information provided in this webcast is not intended as a substitute for your physician’s guidance and care.
URL:https://liferaftgroup.org/event/lrg-webcast-series-updates-on-the-temozolomide-trial/
CATEGORIES:Education,Webcast
ATTACH;FMTTYPE=image/jpeg:https://liferaftgroup.org/wp-content/uploads/2019/07/sicklick-temozolomide-webcast.jpg
ORGANIZER;CN="Sara Rothschild":MAILTO:srothschild@liferaftgroup.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20190909T120000
DTEND;TZID=America/New_York:20190909T130000
DTSTAMP:20260504T201330
CREATED:20190816T164240Z
LAST-MODIFIED:20190911T172010Z
UID:10000040-1568030400-1568034000@liferaftgroup.org
SUMMARY:LRG Webcast Series: Medicare 101
DESCRIPTION:Medicare 101: An Overview of the A\, B\, C\, and Ds of Medicare\n\nThe A B C’s of Medicare: Everything you need to know\nWhat is Medicare\, am I eligible and how do I enroll?\nWhat does Medicare cover?\nHow much does it cost?\nWhich path should I choose – Medigap Supplement Insurance or Medicare Advantage Plan?\nHow about Prescription Drug coverage?\nFinancial Assistance Programs to help with Medicare costs\n\nRECAP HERE\n\nThere will be a 15 minute Q & A at the end of the presentation. \nAbout the Presenter:\nKathy Sarmiento has been working for the Alliance for Aging for fifteen years.  The Alliance for Aging is the non-profit Area Agency on Aging for Miami-Dade and Monroe Counties in Florida. In her role as the SHINE Liaison\, Kathy manages the all aspects of the free SHINE Medicare counseling program. Kathy also manages the Benefits Enrollment Center at the Alliance for Aging. The Benefits Enrollment Center is a grant from the National Council on Aging to provide five core benefits to financially needy Medicare beneficiaries. Those five core benefits are Medicaid\, food assistance\, assistance paying for Medicare\, Prescription Drug assistance and assistance paying the light bill. \n\n\nTechnical Tips to Join Meeting:\n\nThis is a web-only meeting\, accessed only by your internet connection. Participants are encouraged to use the web link automatically provided after registration and to use computer speakers (and/or headsets if available) to hear the audio portion of the meeting. Please log in at least ten minutes prior to the start of the webinar.\nPlease ensure you have an updated version of Adobe Flash Player (Google Chrome has Flash built-in).\nIf you are using a mobile device or tablet\, in order to view and hear the conference\, download the ReadyTalk App from your App store.\n\n\nDisclaimer:\nWe cannot provide individual medical advice during this webcast. Information provided in this webcast is not intended as a substitute for your physician’s guidance and care.
URL:https://liferaftgroup.org/event/lrg-webcast-series-medicare-101/
CATEGORIES:Webcast
ATTACH;FMTTYPE=image/jpeg:https://liferaftgroup.org/wp-content/uploads/2019/08/sarmiento-medicare-webcast.jpg
ORGANIZER;CN="Sara Rothschild":MAILTO:srothschild@liferaftgroup.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20190808T140000
DTEND;TZID=America/New_York:20190808T150000
DTSTAMP:20260504T201330
CREATED:20190711T153122Z
LAST-MODIFIED:20190814T174529Z
UID:10000035-1565272800-1565276400@liferaftgroup.org
SUMMARY:LRG Webcast Series: When to Consider Surgery
DESCRIPTION:This webcast will address the issues surrounding the decision to have an operation. Most GIST patients will see a surgeon at some point during their treatment. The decision to consider surgical options depends on a number of factors such as tumor location\, tumor size\, tumor number\, response to drug therapy\, and risk of recurrence. \nDr. Jason Sicklick from Moores Cancer Center at the University of California San Diego will discuss situations when surgical management may be appropriate for managing localized\, regionally advanced and metastatic GIST. \n\nListen To The Webcast\n\nThere will be a 15 minute Q & A at the end of the presentation.\n \nAbout the Presenter:\nJason K. Sicklick\, MD\, FACS\, is an Associate Professor of Surgery\, Division of Surgical Oncology; and Co-Director\, Biorepository and Tissue Technology Shared Resource\, Moores Cancer Center at the University of California\, San Diego\, UC San Diego Health Sciences. \n  \n  \n  \n\nTechnical Tips to Join Meeting:\n\nThis is a web-only meeting\, accessed only by your internet connection. Participants are encouraged to use the web link automatically provided after registration and to use computer speakers (and/or headsets if available) to hear the audio portion of the meeting. Please log in at least ten minutes prior to the start of the webinar.\nPlease ensure you have an updated version of Adobe Flash Player (Google Chrome has Flash built-in).\nIf you are using a mobile device or tablet\, in order to view and hear the conference\, download the ReadyTalk App from your App store.\n\n\nDisclaimer:\nWe cannot provide individual medical advice during this webcast. Information provided in this webcast is not intended as a substitute for your physician’s guidance and care.
URL:https://liferaftgroup.org/event/lrg-webcast-series-when-to-consider-surgery/
CATEGORIES:Events
ATTACH;FMTTYPE=image/jpeg:https://liferaftgroup.org/wp-content/uploads/2019/07/sicklick-surgery-webcast.jpg
ORGANIZER;CN="Sara Rothschild":MAILTO:srothschild@liferaftgroup.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20190618T120000
DTEND;TZID=America/New_York:20190618T130000
DTSTAMP:20260504T201330
CREATED:20190605T174046Z
LAST-MODIFIED:20190814T174912Z
UID:10000028-1560859200-1560862800@liferaftgroup.org
SUMMARY:Symptom and Side Effect Management
DESCRIPTION:Listen to the Webcast\n \nGIST and its treatment can cause a variety of symptoms. Adequate management of symptoms can improve a patient’s quality of life. Proper management can also allow the patient to remain on treatment without a decrease in dosage\, interruption of treatment\, or even the discontinuation of treatment. Staying on treatment as prescribed gives patients the best chance of a good outcome and in some cases has been shown to improve survival rates. \nIn this webcast\, Dr. Lori Williams\, Associate Professor in the Department of Symptom Research at MD Anderson Cancer Center\, will review common symptoms associated with GIST and some of its treatments. She will present methods patients can use to self-manage symptoms as well as how to discuss and when to report symptoms to health care providers. \nPete Knox\, LRG Senior Director of Research\, will also share an update on our interactive side effects management platform\, SideEQ. This platform is a great tool to allow patients to optimize their overall health by learning and sharing tips with others on how to manage side effects. To learn more\, visit MySideEQ.org \nThere will be a 15 minute Q & A at the end of the presentation. \nAbout the Presenters:\nDr. Lori Williams is an Associate Professor in the Department of Symptom Research at The University of Texas MD Anderson Cancer Center and an Advanced Oncology Certified Nurse. She has worked in oncology nursing for more than 35 years. She is a member of the executive board of the Patient Advocate and National Patient Advocate Foundations and a secretary-treasurer of the Board of the Oncology Nursing Certification Corporation. Her current work at MD Anderson involves the study of symptoms of cancer and cancer treatment. She is currently working with leadership at MD Anderson to institute routine clinical symptom monitoring for all patients. \nAs Senior Director of Research\, Pete Knox is a key member of the Real World Evidence Team\, utilizing his analytic skills to provide strategic oversight of the Life Raft Group’s research and data platforms. In this role\, he identifies and develops potential collaborations with institutions and organizations that utilize data to advance research\, with the goal of improving overall survival and quality of life for GIST patients. \n\nTechnical Tips to Join Meeting:\n\nThis is a web only meeting\, accessed only by your internet connection. Participants are encouraged to use the web link automatically provided after registration and to use computer speakers (and/or headsets if available) to hear the audio portion of the meeting. Please log in at least ten minutes prior to the start of the webinar.\nPlease ensure you have an updated version of Adobe Flash Player (Google Chrome has Flash built in).\nIf you are using a mobile device or tablet\, in order to view and hear the conference\, download the ReadyTalk App from your App store.\n\n\nDisclaimer:\nWe cannot provide individual medical advice during this webcast. Information provided in this webcast is not intended as a substitute for your physician’s guidance and care.
URL:https://liferaftgroup.org/event/symptom-and-side-effect-management/
CATEGORIES:Events
ATTACH;FMTTYPE=image/jpeg:https://liferaftgroup.org/wp-content/uploads/2019/06/williams.jpg
ORGANIZER;CN="Sara Rothschild":MAILTO:srothschild@liferaftgroup.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20190508T130000
DTEND;TZID=America/New_York:20190508T130000
DTSTAMP:20260504T201330
CREATED:20190423T160916Z
LAST-MODIFIED:20190423T161403Z
UID:10000004-1557320400-1557320400@liferaftgroup.org
SUMMARY:Ask the Experts LIVE
DESCRIPTION:Want to know more about GIST?\nDo you have some burning questions to ask GIST experts?\n\nMembers of the LRG GIST Global Expert Surveillance Team\nwill be at the LRG offices on May 8th at 1:00 pm ET for an\nAsk the Experts LIVE event to be broadcast on YouTube Live.\n\n\n\n \nDr. Gary Schwartz\nColumbia University Irving Medical Center \n\nDr. Jason Sicklick\nMoores Cancer Center\, University of California\, San Diego\n\n\nDr. Jonathan Trent\nSylvester Comprehensive Cancer Center \n\nRegister\n\n\n\n\nWe welcome you to submit your questions ahead of time.\nQuestions can be emailed to Sara Rothschild at srothschild@liferaftgroup.org.\nViewers can also ask questions live during the event.\n\n\nDisclaimer:\nWe cannot provide individual medical advice during this live event. Information provided is not intended as a substitute for your physician’s guidance and care.
URL:https://liferaftgroup.org/event/ask-the-experts-live/
LOCATION:You Tube Live
CATEGORIES:Education,Events
ATTACH;FMTTYPE=image/jpeg:https://liferaftgroup.org/wp-content/uploads/2019/04/ask-the-experts-live-eventpg.jpg
ORGANIZER;CN="Sara Rothschild":MAILTO:srothschild@liferaftgroup.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20190503T130000
DTEND;TZID=America/New_York:20190503T140000
DTSTAMP:20260504T201330
CREATED:20190418T143423Z
LAST-MODIFIED:20190507T155606Z
UID:10000019-1556888400-1556892000@liferaftgroup.org
SUMMARY:LRG Webcast: Genetic Testing and SDHx Mutations
DESCRIPTION:Genetic Testing and SDHx Mutations:\nWhat do they have to do with PGL/GIST/Pheos?\nLISTEN TO WEBCAST\n\nThis webcast will highlight how SDHx mutations impact risks for paraganglioma\, pheochromocytomas\, and GIST. We’ll discuss why genetic testing is helpful for any diagnosis of GIST\, paraganglioma or pheochromocytoma\, and what the SDHx genes have to do with tumor risk. We’ll discuss what types of tumors are associated with mutations in the SDHx genes\, and how different SDHx genes (SDHA\, SDHB\, SDHC\, SDHD\, SDHAF2) have different tumor and location risks. This webcast will highlight recommendations for screening and current research initiatives for SDHx and paragangliomas.\n\nAbout the Presenter:\nSamantha Greenberg is a board-certified genetic counselor who oversees the SDHx clinic and specializes in paraganglioma research at Huntsman Cancer Institute. She graduated with a Master’s Degree in Human Genetics and a Master’s of Public Health from the University of Michigan\, and a Bachelor’s Degree in neuroscience from the same university. Prior to her graduate training\, she taught 7th grade science in Tulsa\, Oklahoma\, through Teach for America. At Huntsman\, Samantha also continues public health genomics work with the Department of Health focused on rural clinician education and programming. She has worked to expand cancer genetics’ role in genitourinary cancers\, and oversees the VHL Clinical Care Center.\n\nTechnical Tips to Join Meeting:\n\nThis is a web only meeting\, accessed only by your internet connection. Participants are encouraged to use the web link automatically provided after registration and to use computer speakers (and/or headsets if available) to hear the audio portion of the meeting. Please log in at least ten minutes prior to the start of the webinar.\nPlease ensure you have an updated version of Adobe Flash Player (Google Chrome has Flash built in).\nIf you are using a mobile device or tablet\, in order to view and hear the conference\, download the ReadyTalk App from your App store.\n\nDisclaimer:\nWe cannot provide individual medical advice during this webcast. Information provided in this webcast is not intended as a substitute for your physician’s guidance and care.
URL:https://liferaftgroup.org/event/lrg-webcast-genetic-testing-and-sdhx-mutations/
CATEGORIES:Education,Events,Webcast
ATTACH;FMTTYPE=image/jpeg:https://liferaftgroup.org/wp-content/uploads/2019/04/greenberg-event.jpg
ORGANIZER;CN="Sara Rothschild":MAILTO:srothschild@liferaftgroup.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20190313T120000
DTEND;TZID=America/New_York:20190313T130000
DTSTAMP:20260504T201330
CREATED:20190306T165005Z
LAST-MODIFIED:20190603T145758Z
UID:10000014-1552478400-1552482000@liferaftgroup.org
SUMMARY:LRG Webcast: The Biology of GIST
DESCRIPTION:What Every Patient Needs to Know\nWondering what in the world Gastrointestinal Stromal Tumor (GIST) is? \nJoin longtime friend of the Life Raft Group and LRG Science Team member\, Dr. David Josephy\, as he presents the basics of cell biology in cancer\, focusing on GIST. \nPresented in an easy-to-understand way\, Dr. Josephy unravels the mystery behind the differences between sarcomas and carcinomas; protein expression and the role of immunohistochemistry in diagnosis; the significance of mutations in the KIT and PDGFRA genes and the mechanism of action of tyrosine kinase inhibitor drugs. \nSound complicated? Dr. Josephy’s approachable style will decode the terminology and concepts for you\, whether you are newly diagnosed or are a long-term survivor. \nThere will be at 15 min Q&A at the end of his presentation. \n\nListen to the Webcast\n\nAbout the Presenter:\nDavid Josephy is a Professor of Molecular and Cellular Biology at the University of Guelph\, where he has taught for more than 35 years. He has been President of GIST Sarcoma Life Raft Group Canada (LRGC) since its inception in 2008. \nIn 2010\, David spent a sabbatical term working in the laboratory of Dr. Jonathan Fletcher\, a leading GIST researcher at Brigham and Women’s Hospital in Boston. \nDavid is a member of the Science Team of The Life Raft Group (USA) and collaborates with GIST patient support groups around the world. His research interests are in the field of Molecular Toxicology. He is particularly interested in the scientific basis for development of new small-molecule drugs for GIST. \n\n\nTechnical Tips to Join Meeting:\n\nThis is a web only meeting\, accessed only by your internet connection. Participants are encouraged to use the web link automatically provided after registration and to use computer speakers (and/or headsets if available) to hear the audio portion of the meeting. Please log in at least ten minutes prior to the start of the webinar.\nPlease ensure you have an updated version of Adobe Flash Player (Google Chrome has Flash built in).\nIf you are using a mobile device or tablet\, in order to view and hear the conference\, download the ReadyTalk App from your App store.\n\n\nDisclaimer:\nWe cannot provide individual medical advice during this webcast. Information provided in this webcast is not intended as a substitute for your physician’s guidance and care.
URL:https://liferaftgroup.org/event/lrg-webcast-the-biology-of-gist/
CATEGORIES:Education,Events,Webcast
ATTACH;FMTTYPE=image/jpeg:https://liferaftgroup.org/wp-content/uploads/2018/08/feature-lrg-webcast-series-rev.jpg
ORGANIZER;CN="Sara Rothschild":MAILTO:srothschild@liferaftgroup.org
END:VEVENT
END:VCALENDAR